Cargando…
PD‐1 Pandemonium at the American Association for Cancer Research Annual Meeting
This editorial describes the results of discussions between the U.S. FDA Oncology Center of Excellence and members of six pharmaceutical companies—a forum aptly named PD‐1 Pandemonium—regarding development and regulatory approvals of immune checkpoint inhibitors.
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons, Inc.
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6516112/ https://www.ncbi.nlm.nih.gov/pubmed/31088980 http://dx.doi.org/10.1634/theoncologist.2019-0281 |